Eli Lilly ( LLY) has announced it's been granted a temporary restraining order to halt production of a generic version of its osteoporosis drug Evista.

According to Lilly, Teva Pharmaceuticals ( TEVA) had indicated it was ready to launch its version of Evista before outstanding patent litigation had been resolved. The U.S. District Court for the Southern District of Indiana is hearing the matter.

"We appreciate the Court issuing the temporary restraining order and look forward to completing the trial and vindicating our patent rights," said Robert A. Armitage, senior vice president and general counsel for Lilly.

It's been a busy few months for Teva in terms of generic-drug efforts. Last month, Teva announced it had received final FDA approval for a generic version of GlaxoSmithKline's ( GSK) migraine drug Imitrex, and in January it received approval for a version of Janssen's antipsychotic agent Risperdal. And in late December, the FDA granted tentative approval to market a version of AstraZeneca's ( AZN) Seroquel.

Lilly shares were recently up 6% to $29.66. Teva shares were down 0.2% to $43.16.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief